跳至主要内容
临床试验/NCT01072604
NCT01072604已完成1 期

An Open Label Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Aspirin Tablets and Aspirin Dry Granules in Healthy Adult Subjects

Bayer0 个研究点目标入组 30 人开始时间: 2009年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Bayer
入组人数
30
主要终点
Bioequivalence of new formula aspirin relative to the established commercial aspirin plain tablet and aspirin dry granules when taken orally by healthy adult subjects

研究概览

简要总结

To determine the bioequivalence of new formula of aspirin relative to the established commercial aspirin plain tablet and aspirin dry granules when taken orally by healthy adult subjects

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male and female subjects between 18 to 55 years of age inclusive with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs)
  • Results of screening and clinical laboratory tests are within normal range or considered not clinically significant by the Principal Investigator or Sponsor
  • Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera, or a double barrier and have a negative pregnancy test at Screening and Day 0 for each Dosing Period. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy
  • Be willing to participate in all scheduled visits, treatment plan, laboratory tests and other trial procedures according to the clinical protocol

排除标准

  • History of hypersensitivity to aspirin (ASA), NSAIDs, acetaminophen and similar pharmacological agents or components of the products
  • Eighteen to twenty year olds with a viral infection, with or without fever, at the time of dosing
  • Syndromes of asthma, rhinitis or nasal polyps
  • Females who are pregnant or lactating
  • Have taken ASA, ASA-containing products, acetaminophen or any other NSAID (OTC or prescription) 7 days prior to dosing or during the treatment period, other than trial treatment
  • Smokers or currently consuming any type of tobacco product(s) including any smoking cessation nicotine-containing product (e.g., nicotine patch, nicotine gum)

研究组 & 干预措施

Arm 1

Experimental

干预措施: Acetylsalicylic acid (Aspirin, BAY1019036) (Drug)

Arm 2

Experimental

干预措施: Acetylsalicylic acid (Aspirin, BAY1019036) (Drug)

Arm 3

Active Comparator

干预措施: Acetylsalicylic acid (Aspirin, BAYE4465) (Drug)

Arm 4

Active Comparator

干预措施: Acetylsalicylic acid (Aspirin, BAYE4465) (Drug)

结局指标

主要结局

Bioequivalence of new formula aspirin relative to the established commercial aspirin plain tablet and aspirin dry granules when taken orally by healthy adult subjects

时间窗: 24 hours

次要结局

  • To assess safety and tolerability of the new aspirin formula(24 hours)
  • To assess additional pharmacokinetic parameters(24 hours)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验